tn ional Application No FL 1/GB2004/005080

A. CLASSI IPC 7	FICATION OF SUBJECT MATTER CO7F9/00 A61K31/28 A61P5/00	A61P25/00					
According to International Patent Classification (IPC) or to both national classification and IPC							
B. FIELDS							
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07F A61K A61P							
	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic da	ata base consulted during the international search (name of data bas	se and, where practical, search terms used	'				
EPO-Internal, CHEM ABS Data							
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT						
Category *	Citation of document, with Indication, where appropriate, of the rela	ovant passages	Relevant to claim No.				
P,X	SCHMID, ANNETTE C. ET AL: "Bisperoxovanadium compounds are PTEN inhibitors" FEBS LETTERS, 566(1-3), 35-38 CO FEBLAL; ISSN: 0014-5793, 2004, XP the whole document	DEN:	1-12				
х	NOLTE, LORRAINE A. ET AL: "A peroxovanadium compound stimulate glucose transport as powerfully a and contractions combined" DIABETES, 52(8), 1918-1925 CODEN ISSN: 0012-1797, 2003, XP00231847 the whole document	1-8,12					
X Furti	ner documents are listed in the continuation of box C.	Patent family members are listed in	n annex.				
*Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the International filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document repring to an oral disclosure, use, exhibition or other means 'P' document published prior to the International filing date but tater than the priority date claimed 'I' later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered to invention cannot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such documents such documents is combined with one or more other such documents in the art. 'B' coursent member of the same patent family							
ļ		Date of malling of the international sea					
	actual completion of the International search March 2005	10/03/2005					
Name and r	nailing address of the ISA European Patent' Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Rinkel, L					

Form PCT/ISA/210 (second sheet) (January 2004)

Application No /GB2004/005080

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Refevant to claim No.
X	BAND, CHRISTIAN J. ET AL: "Early signaling events triggered by peroxovanadium 'bpV(phen)! are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase (s) by bpV(phen)" MOLECULAR ENDOCRINOLOGY , 11(13), 1899-1910 CODEN: MOENEN; ISSN: 0888-8809, 1997, XP002318471 the whole document	1-8,12
X	BAND, CHRISTIAN J. ET AL: "Phosphatidylinositol 3'-kinase and p70s6k are required for insulin but not bisperoxovanadium 1,10-phenanthroline (bpV(phen)) inhibition of insulin-like growth factor binding protein gene expression. Evidence for MEK-independent activation of mitogen-activated protein kinase by bpV(phen)" JOURNAL OF BIOLOGICAL CHEMISTRY, 272(1), 138-145 CODEN: JBCHA3; ISSN: 0021-9258, 1997, XP002318472 cited in the application the whole document	1-8,12
X	US 2003/055106 A1 (FAURE, ROBERT ET AL) 20 March 2003 (2003-03-20) the whole document	1-8,12
X	BARAT, CORINNE ET AL: "Treatment of Human T Cells with Bisperoxovanadium Phosphotyrosyl Phosphatase Inhibitors Leads to Activation of Cyclooxygenase-2 Gene" JOURNAL OF BIOLOGICAL CHEMISTRY, 278(9), 6992-7000 CODEN: JBCHA3; ISSN: 0021-9258, 2003, XP002318473 the whole document	1-8,12
X	WO 00/57860 A2 (CENTRE FOR TRANSLATIONAL RESEARCH IN CANCER, CAN.) 5 October 2000 (2000-10-05) the whole document	1-8,12
Ρ,Χ	WO 2004/018655 A2 (NEURONOVA AB, SWED.) 4 March 2004 (2004-03-04) the whole document	1-8,12
	210 (continuation of second sheet) (legister 2004)	

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

Application No PC1/GB2004/005080

	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	Colourest to stein No.		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	SASAGAWA, TAKAHIRO ET AL: "Bis(6-ethylpicolinato)oxovanadium(IV) complex with normoglycemic activity in KK-Ay mice" JOURNAL OF INORGANIC BIOCHEMISTRY, 88(1), 108-112 CODEN: JIBIDJ; ISSN: 0162-0134, 2002, XP002318474 the whole document	10,12		
x	KOZLOV, ALEXANDER ET AL: "Zeolite-encapsulated vanadium picolinate peroxo complexes active for catalytic hydrocarbon oxidations" JOURNAL OF MOLECULAR CATALYSIS A: CHEMICAL , 137(1-3), 223-237 CODEN: JMCCF2; ISSN: 1381-1169, 1999, XP002318475 the whole document	10		
Ρ,Χ	GB 2 396 106 A (JOHNSON & JOHNSON MEDICAL LIMITED, UK) 16 June 2004 (2004-06-16) the whole document 	1-8,12		
	•			
	-			

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

Application No PC1/GB2004/005080

Patent document cited in search report			Publication date	Patent family member(s)		Publication date		
US 200	03055106	A1	20-03-2003	CA	2280249	A1	12-02-2001	
				ΑU	6550900	Α	13-03-2001	
				BR	0013147	Α	23-07-2002	
				WO	0112180	A2	22-02-2001	
				CA	2314915	A1	12-02-2001	
				EP	1202728	A2	08-05-2002	
				JP	2003506487	T	18-02-2003	
				MX	PA02001481	Α	21-07 - 2003	
				NZ	517159	Α	30-04-2004	
WO 00!	57860	A2	05-10-2000	AU	3412600	Α	16-10-2000	
				CA	2365122	A1	05-10-2000	
				EP	1165098	A2	02-01-2002	
WO 20	04018655	A2	04-03-2004	NONE				
GB 23	96106	A	16-06-2004	WO	2004052412	A1	24-06-2004	

Form PCT/ISA/210 (patent family annex) (January 2004)